Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity
Javitt, JC., Zlateva, GP., Earnshaw, S., Pleil, AM., Graham, C., Brogan, A., Shah, SN., & Adamis, AR. (2008). Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health, 11(4), 563-574.
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Meet the Experts
View All ExpertsRecent Publications
Article
The daily association between affect and alcohol use: A meta-analysis of individual participant data
Article
The use of patient experience feedback in rehabilitation quality improvement and codesign activities
Article
Protection of forest ecosystems in the eastern United States from elevated atmospheric deposition of sulfur and nitrogen
Article